ATE348883T1 - Zusammensetzungen und verfahren mit analogen von g-csf - Google Patents

Zusammensetzungen und verfahren mit analogen von g-csf

Info

Publication number
ATE348883T1
ATE348883T1 AT01970897T AT01970897T ATE348883T1 AT E348883 T1 ATE348883 T1 AT E348883T1 AT 01970897 T AT01970897 T AT 01970897T AT 01970897 T AT01970897 T AT 01970897T AT E348883 T1 ATE348883 T1 AT E348883T1
Authority
AT
Austria
Prior art keywords
csf
methods
compositions
present
analogues
Prior art date
Application number
AT01970897T
Other languages
English (en)
Inventor
Casim A Sarkar
Douglas A Lauffenburger
Bruce Tidor
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Application granted granted Critical
Publication of ATE348883T1 publication Critical patent/ATE348883T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
AT01970897T 2000-09-08 2001-09-10 Zusammensetzungen und verfahren mit analogen von g-csf ATE348883T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23146400P 2000-09-08 2000-09-08

Publications (1)

Publication Number Publication Date
ATE348883T1 true ATE348883T1 (de) 2007-01-15

Family

ID=22869337

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01970897T ATE348883T1 (de) 2000-09-08 2001-09-10 Zusammensetzungen und verfahren mit analogen von g-csf

Country Status (13)

Country Link
US (4) US6790628B2 (de)
EP (2) EP1317537B1 (de)
JP (2) JP2004524005A (de)
AT (1) ATE348883T1 (de)
AU (5) AU9096001A (de)
CA (2) CA2421757A1 (de)
CY (1) CY1107556T1 (de)
DE (1) DE60125381T2 (de)
DK (1) DK1317537T3 (de)
ES (1) ES2276822T3 (de)
MX (2) MXPA03002045A (de)
PT (1) PT1317537E (de)
WO (2) WO2002020767A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507705B2 (en) * 1997-10-02 2009-03-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
EP1425304B9 (de) 2001-07-11 2010-09-08 Maxygen, Inc. G-csf konjugate
AU2003210806A1 (en) * 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
JP4783013B2 (ja) * 2002-07-30 2011-09-28 ステム セル セラピューティクス インコーポレイテッド 多能性神経幹細胞からの希突起神経膠細胞産生
NZ538421A (en) * 2002-08-23 2008-08-29 Inst Medical W & E Hall A method of treatment and prophylaxis
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
AU2003299430B2 (en) * 2002-12-31 2009-01-08 Neurovision-Pharma Gmbh Methods of treating neurological conditions with hematopoeitic growth factors
US7695723B2 (en) * 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7785601B2 (en) * 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
EP2196210A1 (de) * 2003-10-24 2010-06-16 Nora, LLC Verfahren zur Reduzierung der Wahrscheinlichkeit von Präeklampsie bei einer Person, die darauf angewiesen ist
US8338373B2 (en) * 2003-10-24 2012-12-25 Nora Therapeutics, Inc. Method for reducing the risk of spontaneous abortion in a human female subject
US20090226397A1 (en) 2003-10-24 2009-09-10 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
EP1586334A1 (de) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF Konjugate mit PEG
KR20080027291A (ko) 2005-06-01 2008-03-26 맥시겐 홀딩스 엘티디 피이지화된 지-씨에스에프 폴리펩타이드 및 그 제조방법
US20070092482A1 (en) * 2005-08-04 2007-04-26 Bossard Mary J Conjugates of a G-CSF moiety and a polymer
KR20070019524A (ko) * 2005-08-12 2007-02-15 메디제네스(주) 암 진단 마커 및 방법
CN101381371B (zh) * 2007-09-05 2011-05-18 上海医药工业研究院 二硫杂环戊烯并吡咯酮类化合物及其制备方法和应用
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US8112365B2 (en) * 2008-12-19 2012-02-07 Foster Scott C System and method for online employment recruiting and evaluation
EP2542574B1 (de) 2010-03-04 2017-08-09 Pfenex Inc. Verfahren zur herstellung eines löslichen und rekombinanten interferonproteins ohne denaturierung
JP5932670B2 (ja) * 2010-03-11 2016-06-08 ライナット ニューロサイエンス コーポレイション ｐＨ依存性の抗原結合を有する抗体
AU2011235210B2 (en) 2010-04-01 2015-07-16 Pfenex Inc. Methods for G-CSF production in a Pseudomonas host cell
US8892184B2 (en) 2010-10-18 2014-11-18 Siemens Medical Solutions Usa, Inc. Systems and methods for reducing interference in a dual modality imaging system
SG192117A1 (en) 2011-01-28 2013-08-30 Sanofi Sa Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
US9320777B2 (en) 2011-05-13 2016-04-26 Bolder Biotechnology, Inc. Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
HUE069234T2 (hu) 2011-09-16 2025-02-28 Regeneron Pharma Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával
KR101402272B1 (ko) * 2011-11-25 2014-06-11 동의대학교 산학협력단 신규한 ｇ-ｃｓｆ 폴리뉴클레오티드 및 이의 용도
EP3539374A1 (de) 2012-03-16 2019-09-18 Regeneron Pharmaceuticals, Inc. Nicht-menschliche tiere zur expression ph-sensitiver immunoglobulinsequenzen
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
WO2013138681A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
EP2825036B1 (de) 2012-03-16 2018-05-02 Regeneron Pharmaceuticals, Inc. Durch histidin manipulierte leichtkettige antikörper und genetisch modifizierte nager zur erzeugung davon
JP2013253842A (ja) 2012-06-06 2013-12-19 Univ Of Tokyo ｐＨ依存的に標的分子に結合するペプチドのスクリーニング方法
KR102083046B1 (ko) * 2012-06-07 2020-02-28 칠드런＇스 하스피틀 로스 앤젤레스 레티노이드 작용제를 이용하여 호중구감소증을 치료하기 위한 방법
US9540449B2 (en) 2012-08-13 2017-01-10 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies with pH-dependent binding characteristics
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
US10494442B2 (en) 2013-06-07 2019-12-03 Sanofi Biotechnology Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
CN118105480A (zh) 2013-11-12 2024-05-31 赛诺菲生物技术公司 用于与pcsk9抑制剂一起使用的给药方案
MX2016010699A (es) 2014-02-18 2017-10-11 Children's Hospital Los Angeles Composiciones y metodos para tratar neutropenia.
CA3124228C (en) 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
KR20230074283A (ko) 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
WO2016068919A1 (en) 2014-10-29 2016-05-06 Geovax, Inc. Combination therapy for treating viral reservoirs
CA2979702A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
JP2018523684A (ja) 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
US11229683B2 (en) 2015-09-18 2022-01-25 Bolder Biotechnology, Inc. Hematopoietic growth factor proteins and analogs thereof and angiotensin converting enzyme inhibitors for treatment of radiation exposure
AU2016342209B2 (en) * 2015-10-19 2020-12-17 Sandoz Ag Improved coding sequence for human G-CSF
WO2018138267A1 (en) * 2017-01-27 2018-08-02 Cinfa Biotech S.L. Method for determining the efficacy of a g-csf containing composition

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
DK203187A (da) 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
AU7675487A (en) 1986-08-11 1988-05-19 Cetus Corporation Expression of granulocyte colony-stimulating factor
NO176799C (no) 1986-12-23 1995-05-31 Kyowa Hakko Kogyo Kk DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid
US5214132A (en) 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
GB2213821B (en) 1987-12-23 1992-01-02 British Bio Technology Synthetic human granulocyte colony stimulating factor gene
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
KR0133561B1 (ko) 1988-05-13 1998-04-21 스티븐 엠. 오드레 과립구 군체 자극인자의 정제방법
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
WO1990006952A1 (fr) * 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
JPH04164098A (ja) * 1990-03-07 1992-06-09 Kirin Amgen Inc 化学修飾顆粒球コロニー刺激因子誘導体
GB9107846D0 (en) * 1990-04-30 1991-05-29 Ici Plc Polypeptides
DE4014750A1 (de) * 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
DE4105480A1 (de) 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
IT1285405B1 (it) * 1995-06-06 1998-06-03 Alza Corp Modificazione di farmaci polipeptidici per accrescere il flusso per elettrotrasporto.
WO1997012977A1 (en) * 1995-10-05 1997-04-10 G.D. Searle & Co. Novel g-csf receptor agonists
AU770131B2 (en) * 1999-01-06 2004-02-12 Xencor, Inc. Nucleic acids and proteins corresponding to mutants of G-CSF with granulopoietic activity
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
DE102007031995A1 (de) * 2007-07-09 2009-01-15 Moeller Gmbh Steuervorrichtung für ein Schaltgerät mit Anzugs- und/oder Haltespule sowie Verfahren zum Steuern des durch die Spule fließenden Stroms

Also Published As

Publication number Publication date
ES2276822T3 (es) 2007-07-01
PT1317537E (pt) 2007-02-28
US20050123508A1 (en) 2005-06-09
WO2002020767A2 (en) 2002-03-14
CY1107556T1 (el) 2013-03-13
AU2006201824A1 (en) 2006-05-25
EP1319182A2 (de) 2003-06-18
US6790628B2 (en) 2004-09-14
US6946548B2 (en) 2005-09-20
AU9096001A (en) 2002-03-22
US20030166527A1 (en) 2003-09-04
WO2002020766A3 (en) 2002-12-05
AU2001290960B2 (en) 2007-11-01
US20020151488A1 (en) 2002-10-17
WO2002020766A2 (en) 2002-03-14
EP1317537B1 (de) 2006-12-20
WO2002020767A3 (en) 2003-02-27
AU9084601A (en) 2002-03-22
MXPA03002046A (es) 2003-07-24
MXPA03002045A (es) 2003-07-24
US7371370B2 (en) 2008-05-13
DE60125381D1 (de) 2007-02-01
CA2421760A1 (en) 2002-03-14
JP2004524005A (ja) 2004-08-12
JP4799803B2 (ja) 2011-10-26
JP2004508044A (ja) 2004-03-18
US20050003453A1 (en) 2005-01-06
DK1317537T3 (da) 2007-04-30
AU2001290846B2 (en) 2006-02-02
CA2421757A1 (en) 2002-03-14
DE60125381T2 (de) 2007-04-12
EP1317537A2 (de) 2003-06-11
US7402304B2 (en) 2008-07-22

Similar Documents

Publication Publication Date Title
ATE348883T1 (de) Zusammensetzungen und verfahren mit analogen von g-csf
DE69230993D1 (de) Rekombinante viren vektoren zur expression in muskelzellen
ATE425181T1 (de) Therapeutische zusammensetzungen aus antikorper und antisens nukleinsäuren gegen serrate
EA200300381A1 (ru) Нуклеиновые кислоты и полипептиды нового рецептора
ATE466085T1 (de) Protease-resistente modifizierte interferon alpha polypeptide
DE602004012424D1 (de) Homogene herstellungen von il-29
FI863971A0 (fi) Farmaceutisk komposition anvaendbar vid behandling av leukopenia.
NZ503235A (en) Amino-terminally truncated RANTES as chemokine antagonists
ATE500266T1 (de) Methode zur verbesserung der wirksamkeit von biologischen antwort-verändernden proteinen und exemplarische muteine
ATE246247T1 (de) Varianten des humanen rekombinanten interferon- gamma (rhu-ifn-gamma) mit erhöhter thermischer stabilität
DE3777845D1 (de) Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.
ATE469170T1 (de) Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
BR0312889A (pt) Polipeptìdeo t20 peguilado
HUT58765A (en) Process for producing peptide compounds and pharmaceutical compositions containing them as active components
DE602006020562D1 (de) Hren dafür
PH12022553408A1 (en) Cytokine conjugates
ATE363488T1 (de) Zusammensetzungen von stammzellfaktor (scf)- analogen und auf diese bezogene verfahren
DE69636052D1 (de) Mpl-liganden analoga
RU2336279C2 (ru) БЕЛОК IFNAB-BPI, ЕГО ПРЕДШЕСТВЕННИК, МОЛЕКУЛА ДНК, ЭКСПРЕССИРУЮЩИЙ ВЕКТОР, СПОСОБ ПРОДУЦИРОВАНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ИНГИБИРОВАНИЯ АКТИВНОСТИ IFN-α ИЛИ IFN-β
DE69529750D1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
NO20060675L (no) Forbedrede, rekombinante, humane interferon-beta-lb-polypeptider
NO874704D0 (no) Minaktivin fremstilt ved rekombinant dna-teknikk.
ATE399794T1 (de) Modifizierter granulozyten stimulierender factor (g-csf) mit verringerter immunogenität
WO2003087318A3 (en) Truncated 24 kda basic fibroblast growth factor

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1317537

Country of ref document: EP